The March 2016 British National Formulary (BNF) provides up-to-date, practical guidance on prescribing, dispensing, and administering medicines. This essential reference reflects current best practice as well as legal and professional guidelines relating to the uses of medicines.
Please note: NICE have altered their distribution arrangement for England, and eligible health professionals now receive one free print copy of BNF a year - the September issue - to supplement online access. The March edition is printed as usual, and you can buy your copy here.
BNF 71 (March 2016) has been revised and revalidated to reflect changes in product availability, emerging safety concerns and shifts in clinical practice. Access to the latest edition of the BNF is vital for healthcare professionals, as there are a large number of updates from one edition to the next.Some of the significant content updates for BNF 71 include:
- New safety information, including:
- very low risk of subacute cutaneous lupus erythematosus with proton pump inhibitors
- risk of severe bradycardia and heart block when hepatitis C drugs taken with amiodarone hydrochloride
- risk of diabetic ketoacidosis with sodium glucose co-transporter 2 (SGLT2) inhibitors
- increased reports of eye irritation since reformulation of latanoprost (Xalatan®)
- Updated advice for further measures to minimise risk of osteonecrosis of the jaw associated with use of denosumab and intravenous bisphosphonates
- Updated safety information on risk factors for uterine perforation associated with the use of intra-uterine contraception (intra-uterine contraceptive devices (copper) and levonorgestrel)
- Inclusion of monitoring recommendations for risks of cardiac failure with crizotinib
- Updates to immunisation schedule (Summer 2015): meningococcal group B vaccine, meningococcal groups A, C, W135 and Y vaccine, and influenza vaccine added
- Addition of new preparations including Otezla® (apremilast), Kengrexal® (cangrelor), Velphoro® (sucroferric oxyhydroxide), and more
- Significant dose changes including avanafil, colistimethate sodium (Promixin®), oseltamivir, and more
Improvements in the new edition
Since the launch of the new format BNF we have actively sought your comments and feedback, and as a result have made a number of improvements to the March edition.
- The second colour on the book pages has changed back to the blue you prefer
- We’ve addressed many of your issues with preparations
- We’ve completely reviewed the indexing, including many new entries to make locating content easier
- More information included in ‘prescribing and dispensing’, helping you select products more easily
- A number of design features have been added and improved to aid navigation around pages.
The BNF evaluates clinical evidence from diverse sources with information validated by a network of clinical experts and published under the authority of a Joint Formulary Committee